Global Biotherapeutics Technologies, Pfizer Dublin, Ireland.
Front Immunol. 2012 Nov 15;3:342. doi: 10.3389/fimmu.2012.00342. eCollection 2012.
Antibodies are the fastest-growing segment of the biologics market. The success of antibody-based drugs resides in their exquisite specificity, high potency, stability, solubility, safety, and relatively inexpensive manufacturing process in comparison with other biologics. We outline here the structural studies and fundamental principles that define how antibodies interact with diverse targets. We also describe the antibody repertoires and affinity maturation mechanisms of humans, mice, and chickens, plus the use of novel single-domain antibodies in camelids and sharks. These species all utilize diverse evolutionary solutions to generate specific and high affinity antibodies and illustrate the plasticity of natural antibody repertoires. In addition, we discuss the multiple variations of man-made antibody repertoires designed and validated in the last two decades, which have served as tools to explore how the size, diversity, and composition of a repertoire impact the antibody discovery process.
抗体是生物制品市场中增长最快的部分。与其他生物制品相比,基于抗体的药物之所以成功,是因为其具有高度的特异性、高效性、稳定性、溶解性、安全性和相对廉价的制造工艺。在这里,我们概述了定义抗体如何与各种靶标相互作用的结构研究和基本原则。我们还描述了人类、小鼠和鸡的抗体库和亲和力成熟机制,以及在骆驼科动物和鲨鱼中使用新型单域抗体。这些物种都利用不同的进化解决方案来产生特异性和高亲和力的抗体,并说明了天然抗体库的可塑性。此外,我们还讨论了在过去二十年中设计和验证的多种人工抗体库的变体,这些变体已成为探索库的大小、多样性和组成如何影响抗体发现过程的工具。